MCH antagonists and their use in the treatment of obesity

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S237800, C514S238500, C514S318000, C514S331000, C544S129000, C544S163000, C544S165000, C544S336000, C544S295000, C544S357000, C544S399000, C544S400000, C546S197000, C546S201000, C546S230000, C546S231000, C546S234000

Reexamination Certificate

active

07452891

ABSTRACT:
The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

REFERENCES:
patent: 2004/0063779 (2004-04-01), Dollinger et al.
Wolff, Manfred E. Burger's Medicinal Chemistry, 5th Ed. Part 1, pp. 975-977 (1995).
Banker et al. “Modern Pharmaceutics”, 3rd Ed. p. 596 (1996).
Vippagunta et al. Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

MCH antagonists and their use in the treatment of obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with MCH antagonists and their use in the treatment of obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MCH antagonists and their use in the treatment of obesity will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4034220

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.